Cardiologia

Estudo | Consumo de café não tem relação com o aumento da incidência de taquiarritmias.

20 Jul, 2021 | 10:41h

Coffee Consumption and Incident Tachyarrhythmias: Reported Behavior, Mendelian Randomization, and Their Interactions – JAMA Internal Medicine

Comentário convidado: Another Cup of Coffee Without an Arrhythmia, Please

Entrevista com o autor: Coffee Consumption and Incident Tachyarrhythmias

 

Comentário no Twitter

Good news for coffee drinkers ☕️☕️
Debunking the dogma that coffee increases the risk of heart rhythm disturbances, from >386,000 people, 4.5 year follow-up, including putative genomic risk variants@JAMAInternalMed https://t.co/9bBihDfB3A @uk_biobank pic.twitter.com/V6yGeNg7Fp

— Eric Topol (@EricTopol) July 19, 2021

 

---

Diretriz Científica AHA/ASA | Atenção primária a pacientes adultos pós-AVC.

19 Jul, 2021 | 09:55h

Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association – Stroke

Comunicado de imprensa: Comprehensive primary care is vital to holistic care and optimal recovery after a stroke – American Heart Association

 

Comentário no Twitter

Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association https://t.co/moIZ1W2cXL @American_Heart @American_Stroke pic.twitter.com/jWOK8Fz0vM

— Stroke AHA/ASA (@StrokeAHA_ASA) July 15, 2021

 

---

M-A | Relação risco/benefício das estatinas na prevenção primária de doença cardiovascular é geralmente favorável.

19 Jul, 2021 | 09:51h

Comunicado de imprensa: New study suggests benefit-to-harm balance of statins for healthy adults ‘generally favorable’ – BMJ

Estudo original: Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses – The BMJ

 

Comentário no Twitter

Statins are associated with a small increased risk of side effects in patients without a history of heart disease, but these effects are mild compared with the potential benefits of treatment in preventing major cardiovascular events, say researchers https://t.co/Yvn7Ojtx2F

— The BMJ (@bmj_latest) July 17, 2021

 

---

Opinião conjunta de ACC/AHA/ESC/WHF | Bem-estar médico: necessidades globais de melhoria na área do cuidado em saúde.

16 Jul, 2021 | 09:48h

Clinician Well-Being: Addressing Global Needs for Improvements in the Health Care Field A Joint Opinion From the American College of Cardiology, American Heart Association, European Society of Cardiology, and the World Heart Federation

 

Comentário no Twitter

ICYMI: Leading CV orgs #AgainstClinicianBurnout recognize that #ClinicianWellBeing is paramount to providing high-quality patient care and are committed to improving the well-being of the CV workforce. ➡️ https://t.co/ufwAWWakPp @JACCJournals @AHAScience @escardio @worldheartfed pic.twitter.com/iyr3BxNRpr

— American College of Cardiology (@ACCinTouch) July 15, 2021

 

---

Avaliação e tratamento da doença arterial periférica: o que todo cardiologista deveria saber.

16 Jul, 2021 | 09:43h

Assessment and management of peripheral arterial disease: what every cardiologist should know – Heart

 

Comentário no Twitter

Assessment and management of peripheral arterial disease: what every cardiologist should know https://t.co/8JFRrXZKfA pic.twitter.com/EvEFW4CA3D

— Heart_BMJ (@Heart_BMJ) June 3, 2021

 

---

Resumo | Definição universal e classificação da insuficiência cardíaca.

14 Jul, 2021 | 11:26h

Universal Definition and Classification of Heart Failure: A Step in the Right Direction from Failure to Function – American College of Cardiology

---

Resumo | Inibidores de SGLT2 e de agonistas receptores de GLP-1: Indicações novas e as já estabelecidas.

14 Jul, 2021 | 11:24h

SGLT2 Inhibitors and GLP-1 Receptor Agonists: Indications – American College of Cardiology

Revisão original: SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications – The Lancet (link para o resumo – $ para o texto completo)

Diretriz relacionada: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

---

Algoritmos de predição de risco SCORE2 | Novos modelos para estimar o risco cardiovascular em 10 anos na Europa.

14 Jul, 2021 | 11:21h

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe – European Heart Journal

Ver também: SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions – European Heart Journal

Editorial: Redefining cardiovascular risk prediction: is the crystal ball clearer now?

Comentário: New risk calculator to save many more lives from heart attack and stroke – University of Cambridge

 

Comentário no Twitter (fio – clique para saber mais)

1/2 SCORE2—a new algorithm derived, calibrated, & validated to predict 10-year risk of first-onset CVD in European populations—enhances the identification of individuals at higher risk of developing CVD across Europe https://t.co/VLYfZyXUek#EHJ #ESCYoung @ehj_ed @rladeiraslopes pic.twitter.com/0yZTJBdKDK

— European Society of Cardiology Journals (@ESC_Journals) June 17, 2021

 

---

Diretriz Científica AHA | Avaliação e direcionamento da saúde cardiovascular em pessoas transgênero e de gênero diverso.

12 Jul, 2021 | 11:27h

Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association – Circulation

Comunicado de imprensa: Discrimination, stress linked to poorer heart health in transgender, gender diverse adults – American Heart Association

---

Revisão | Lipoproteína (a) e doenças cardiovasculares.

12 Jul, 2021 | 11:21h

Lipoprotein(a) and Cardiovascular Diseases – JAMA (gratuito por tempo limitado)

---